VRDN · Viridian Therapeutics
The AI's read
The reported sales and patient count suggest Lumvoa is gaining use. BofA also sees it as a credible rival to Tepezza, which could help Viridian reach more patients. Its market-share estimate and 2027 billing-code expectation are forecasts, not completed outcomes. The reported sales beat is the clearest reason for a favorable read.